| MDL | MFCD08272558 |
|---|---|
| Molecular Weight | 302.34 |
| Molecular Formula | C17H19FN2O2 |
| SMILES | C[C@H](NCC1=CC=C(OCC2=CC=CC=C2F)C=C1)C(N)=O |
Na + channel [1]
Ralfinamide (30 mg/kg, 60 mg/kg; p.o.; twice daily; 42 days) treated with Ralfinamide (80 mg/kg; p.o.; twice daily; 7 days) preoperatively suppresses neuropathic pain
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 81 adult male Sprague–Dawley male rats (260–460 g) [1] |
| Dosage: | 80 mg/kg (7 days preoperatively), 30 mg/kg, 60 mg/kg (postoperative) |
| Administration: | Oral gavage; twice daily; until postoperative day 42 |
| Result: | Suppressed neuropathic pain. |
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01019824 | Newron Pharmaceuticals SPA|Parexel|CliniRx |
Pain
|
March 20, 2009 | Phase 3 |
| NCT00736151 | Newron Pharmaceuticals SPA |
Neuropathic Pain
|
May 2004 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : ≥ 125 mg/mL ( 413.44 mM )
* "≥" means soluble, but saturation unknown.
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.3075 mL | 16.5377 mL | 33.0753 mL |
| 5 mM | 0.6615 mL | 3.3075 mL | 6.6151 mL |
| 10 mM | 0.3308 mL | 1.6538 mL | 3.3075 mL |